Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Revista de Saúde Pública |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0034-89102021000100249 |
Resumo: | ABSTRACT OBJECTIVE To analyze adverse events following immunization (AEFI) against SARS-CoV-2 (covid-19) in the state of Minas Gerais (MG), Brazil. METHODS Epidemiological, descriptive study, with data from e-SUS Notifica (e-SUS Notification) in the state of Minas Gerais from January 20 to March 5, 2021. All suspected cases of AEFI of the covid-19 vaccine in the state were analyzed, totaling 7,305 cases. In this study, we verified the possible correlation between AEFI and the possible immunobiological administered causalities. The variables analyzed for AEFI cases were the immunobiological agent administered (AstraZeneca or Coronavac), the type of event, the evolution of the case, and the time in days since the administration of the immunobiological agent and the onset of symptoms and causality. The incidence rate (IT) was calculated for 100,000 doses applied. RESULTS The occurrence of AEFI as a result of the covid-19 vaccine was frequent (TI: 777.12) in the state. However, only 3% were classified as a severe AEFI, with a 20.85 IT, and 4.71% of them evolved to deaths (8.19 deaths per 100,000 doses applied). Among the deaths analyzed, 84.4% were classified as preexisting conditions caused by factors other than vaccines. Regarding non-serious AEFI, 1.11% occurred by immunization errors (TI: 8.62 EI for every 100 thousand doses applied). CONCLUSION This work encourages the discussion about the importance of recording AEFI related to covid-19 vaccines, demonstrating its safety for the population. |
id |
USP-23_5da0cd3127da9a4fa0ea808168a538a6 |
---|---|
oai_identifier_str |
oai:scielo:S0034-89102021000100249 |
network_acronym_str |
USP-23 |
network_name_str |
Revista de Saúde Pública |
repository_id_str |
|
spelling |
Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas GeraisCoronavirus Infections, prevention & controlVaccines, adverse effectsClinical Trials Data Monitoring CommitteesABSTRACT OBJECTIVE To analyze adverse events following immunization (AEFI) against SARS-CoV-2 (covid-19) in the state of Minas Gerais (MG), Brazil. METHODS Epidemiological, descriptive study, with data from e-SUS Notifica (e-SUS Notification) in the state of Minas Gerais from January 20 to March 5, 2021. All suspected cases of AEFI of the covid-19 vaccine in the state were analyzed, totaling 7,305 cases. In this study, we verified the possible correlation between AEFI and the possible immunobiological administered causalities. The variables analyzed for AEFI cases were the immunobiological agent administered (AstraZeneca or Coronavac), the type of event, the evolution of the case, and the time in days since the administration of the immunobiological agent and the onset of symptoms and causality. The incidence rate (IT) was calculated for 100,000 doses applied. RESULTS The occurrence of AEFI as a result of the covid-19 vaccine was frequent (TI: 777.12) in the state. However, only 3% were classified as a severe AEFI, with a 20.85 IT, and 4.71% of them evolved to deaths (8.19 deaths per 100,000 doses applied). Among the deaths analyzed, 84.4% were classified as preexisting conditions caused by factors other than vaccines. Regarding non-serious AEFI, 1.11% occurred by immunization errors (TI: 8.62 EI for every 100 thousand doses applied). CONCLUSION This work encourages the discussion about the importance of recording AEFI related to covid-19 vaccines, demonstrating its safety for the population.Faculdade de Saúde Pública da Universidade de São Paulo2021-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0034-89102021000100249Revista de Saúde Pública v.55 2021reponame:Revista de Saúde Públicainstname:Universidade de São Paulo (USP)instacron:USP10.11606/s1518-8787.2021055003734info:eu-repo/semantics/openAccessSilva,Roberta Barros daSilva,Thales Philipe Rodrigues daSato,Ana Paula SayuriLana,Francisco Carlos FelixGusmão,Josianne DiasSouza,Janaina Fonseca AlmeidaMatozinhos,Fernanda Penidoeng2021-11-08T00:00:00Zoai:scielo:S0034-89102021000100249Revistahttp://www.scielo.br/scielo.php?script=sci_serial&pid=0034-8910&lng=pt&nrm=isoONGhttps://old.scielo.br/oai/scielo-oai.phprevsp@org.usp.br||revsp1@usp.br1518-87870034-8910opendoar:2021-11-08T00:00Revista de Saúde Pública - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais |
title |
Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais |
spellingShingle |
Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais Silva,Roberta Barros da Coronavirus Infections, prevention & control Vaccines, adverse effects Clinical Trials Data Monitoring Committees |
title_short |
Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais |
title_full |
Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais |
title_fullStr |
Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais |
title_full_unstemmed |
Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais |
title_sort |
Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais |
author |
Silva,Roberta Barros da |
author_facet |
Silva,Roberta Barros da Silva,Thales Philipe Rodrigues da Sato,Ana Paula Sayuri Lana,Francisco Carlos Felix Gusmão,Josianne Dias Souza,Janaina Fonseca Almeida Matozinhos,Fernanda Penido |
author_role |
author |
author2 |
Silva,Thales Philipe Rodrigues da Sato,Ana Paula Sayuri Lana,Francisco Carlos Felix Gusmão,Josianne Dias Souza,Janaina Fonseca Almeida Matozinhos,Fernanda Penido |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Silva,Roberta Barros da Silva,Thales Philipe Rodrigues da Sato,Ana Paula Sayuri Lana,Francisco Carlos Felix Gusmão,Josianne Dias Souza,Janaina Fonseca Almeida Matozinhos,Fernanda Penido |
dc.subject.por.fl_str_mv |
Coronavirus Infections, prevention & control Vaccines, adverse effects Clinical Trials Data Monitoring Committees |
topic |
Coronavirus Infections, prevention & control Vaccines, adverse effects Clinical Trials Data Monitoring Committees |
description |
ABSTRACT OBJECTIVE To analyze adverse events following immunization (AEFI) against SARS-CoV-2 (covid-19) in the state of Minas Gerais (MG), Brazil. METHODS Epidemiological, descriptive study, with data from e-SUS Notifica (e-SUS Notification) in the state of Minas Gerais from January 20 to March 5, 2021. All suspected cases of AEFI of the covid-19 vaccine in the state were analyzed, totaling 7,305 cases. In this study, we verified the possible correlation between AEFI and the possible immunobiological administered causalities. The variables analyzed for AEFI cases were the immunobiological agent administered (AstraZeneca or Coronavac), the type of event, the evolution of the case, and the time in days since the administration of the immunobiological agent and the onset of symptoms and causality. The incidence rate (IT) was calculated for 100,000 doses applied. RESULTS The occurrence of AEFI as a result of the covid-19 vaccine was frequent (TI: 777.12) in the state. However, only 3% were classified as a severe AEFI, with a 20.85 IT, and 4.71% of them evolved to deaths (8.19 deaths per 100,000 doses applied). Among the deaths analyzed, 84.4% were classified as preexisting conditions caused by factors other than vaccines. Regarding non-serious AEFI, 1.11% occurred by immunization errors (TI: 8.62 EI for every 100 thousand doses applied). CONCLUSION This work encourages the discussion about the importance of recording AEFI related to covid-19 vaccines, demonstrating its safety for the population. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-01-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0034-89102021000100249 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0034-89102021000100249 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.11606/s1518-8787.2021055003734 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Faculdade de Saúde Pública da Universidade de São Paulo |
publisher.none.fl_str_mv |
Faculdade de Saúde Pública da Universidade de São Paulo |
dc.source.none.fl_str_mv |
Revista de Saúde Pública v.55 2021 reponame:Revista de Saúde Pública instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Revista de Saúde Pública |
collection |
Revista de Saúde Pública |
repository.name.fl_str_mv |
Revista de Saúde Pública - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
revsp@org.usp.br||revsp1@usp.br |
_version_ |
1748936506548944896 |